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Primary Effusion Lymphoma (PEL) is an HHV-
8-associated lymphoma that usually presents as 
lymphomatous effusion in body cavities. It has an 
extremely aggressive clinical course with a  median 
survival of only 3 months (1-2). PELs are able to 
release several inflammatory cytokines such as IL-
10, IL-6 and VEGF. They act in an autocrine fashion 
and the PEL growth seems to be dependent on their 
production (3).  These cytokines also determine 
phosphorylation and subsequent activation of signal 
trasducer and activator of transcription-3 (STAT3) 
in PEL (4). STAT3 activation plays a critical role in 
promoting PEL survival, since it has been reported 
that its signaling inhibition leads to apoptosis (5). 
STAT3 is constitutively activated also in other 
hematological and epithelial cancers (6). In addition, 
Wang et al. have shown that STAT3 activation in 
tumor cells has an essential role in the negative 
regulation of tumor immunity and in particular on 
functional activity of DC (7). Tumor cell-released 
factors inhibit DC maturation by activating STAT3 
also in these cells, in a paracrine fashion. DC are 
the most potent APC (8) and it is known that the 
function of these cells is impaired in cancer patients 
(9). Nefedova et al. showed that hyperactivation 
of STAT3 is responsible for the abnormal in vitro 
DC differentiation observed in the presence of 
tumor-derived factors (10) and the inhibition 
of Jack2/STAT3 signaling is able to restore DC 
differentiation and function (11). More recently, 
in a  murine model, it was reported that myeloma-
derived factors impaired the differentiation of bone 
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To better understand the molecular mechanisms underlying the dendritic cell (DC) defects in 
cancer, we analyzed which signaling pathway is implicated in the abnormal monocyte differentiation 
into DC determined by the presence of Primary effusion lymphoma (PEL) released factors. Our 
results indicate that the DC, obtained in this condition, together with phenotypic abnormalities and 
reduced allostimulatory function, showed hyperphosphorylation of signal transducer and activator of 
transcription 3 (STAT3) and p38 mitogen-activated protein kinase (MAPK) molecules, in comparison 
to the DC differentiated in the absence of PEL-released factors. The inhibition of p38 MAPK but not 
of STAT3 phosphorylation, with specific inhibitors, was able to revert the effect of the PEL-released 
factors on the DC phenotype. This study suggests that p38 MAPK signaling pathway is an important 
contributor to the abnormal differentiation of DC in PEL.
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immunofluorescence were anti-CD14 and anti-CD1a 
(Becton-Dickinson) and anti-NF-kappaB p65 (Santa 
Cruz). Monoclonal antibodies used for western blotting 
were anti-phosho-p38 MAPK, anti-p38 MAPK, anti-
phospho-ERK and anti-ERK (Cell Signaling), anti-β-actin 
(Sigma) anti-phospho-STAT3 Ty705 and anti-STAT3 total 
protein (BD Bioscience). 
Generation of monocyte-derived DC
To generate monocyte-derived DC, human peripheral 
blood mononuclear cells were isolated by Fycoll-
Paque gradient centrifugation (Pharmacia, Uppsala, 
Sweden) from buffy coats. CD14+ monocytes were 
positively selected using anti-CD14 MAb-conjugated 
magnetic microbeads (Miltenyi Biotec, Auburn, Calif.). 
Purified monocytes were cultured at a density of 1 x106 
cells/3 ml in 12-well plates for 6 days in RPMI 1640 
(Euroclone) containing 10% FCS, 2 mM L-glutamine, 
100 U/ml penicillin G, 100 mg/ml streptomycin, 50 mM 
2-mercaptoethanol (Sigma), and recombinant human 
granulocyte-macrophage colony stimulating factor 
(GM-CSF) plus interleukin 4 (IL-4) (50 ng/ml and 20 
ng/ml respectively, Miltenyi Biotec, Auburn, Calif.). 
PEL supernatants were filtered through 0.2 µm, analyzed 
by PCR to exclude the presence of HHV-8 and added to 
the monocyte culture on day 0 at concentration of 20%. 
Cytokines were replenished every other day by adding 
20% fresh medium to each well.
  
Blocking STAT3 phosphorylation using Janus-Activated 
Kinase 2 inhibitors AG490 and JSI-124
To study the effect of blocking STAT3 activation 
during the DC differentiation in the presence of PEL 
supernatants, CD14+ monocytes were pretreated with 
AG490 at 10 µmol/L for 2 h, the cells were then 
washed with PBS and resuspended in the regular DC 
differentiation cocktail plus PEL supernatants (i.e., 
complete RPMI 1640 with GM-CSF and IL-4) for 6 days. 
JSI-124 (Sigma-Aldrich) inhibitor was used at 0.5 µM, 
added to the differentiation cocktail on day 4 and kept 
for 24 hours. Cell number was determined by viable cell 
count. AG490 had no effect whereas JSI-124 reduced the 
number of cellS recovered.
 
Blocking p38 and ERK phosphorylation
The role of p38 and ERK signaling pathways was 
investigated by blocking p38 MAPK with SB203580 
and with PD98059 at 10 µM (Sigma-Aldrich). Their 
concentration was chosen based on previous studies (16) 
where the inhibitors were titrated for their capacity to 
inhibit the activity of the kinases. Both inhibitors were 
incubated for 30 min at 37°C before culturing monocytes 
with differentiation cocktail plus PEL supernatant for 6 
marrow (BM)-derived DC and this has been shown 
by culturing the murine BM cells with myeloma 
cells, both in a transwell system and by direct 
contact, or by adding to the BM cells the tumor 
culture conditioning medium alone. The myeloma-
derived factors activate p38 mitogen-activated 
protein kinase (MAPK) in these BM-derived DC. 
Its inhibition by the use of specific compounds was 
able to restore the generation of functional DC and 
these results indicate that p38 pathway is a major 
contributor to the DC differentiation abnormalities 
(12). Similar results were obtained with human 
monocyte-derived DC from patients affected by 
multiple myeloma (13). We previously reported 
that soluble factors released by PEL inhibit DC 
differentiation from monocyte precursors and impair 
their function (14). In this study we investigated 
which signal transduction pathway is involved in 
PEL-induced suppression of DC differentiation 
and whether any pharmacological treatment could 
revert the effect of the PEL supernatant. We found 
that, in the presence of PEL-released factors, the 
DC display hyperphosphorylation of STAT3 and 
p38 MAPK molecules. With the use of their specific 
inhibitors, we investigated whether the phenotype 
and the function of DC could be restored. The results 
obtained indicate that p38 inhibitor SB203580 was 
able to revert the inhibition of DC differentiation 
determined by PEL supernatant but, since only the 
phenotype but not the function was restored, we 
conclude that other molecules play a role in the DC 
abnormalities in PEL. It has been reported that DC 
function depends on NF-kappa B activity (15) and 
since STAT3 and p38 MAPK have a negative effect 
on NF-kappaB (8, 16) we investigated the activation 
state of this molecule in DC differentiated in the 
presence and in the absence of PEL supernatant 
with or without STAT3 and p38 MAPK specific 
inhibitors. 
MATERIALS AND METHODS
Cells and antibodies
The PEL cell lines BC-3, JSC-1 and BCP1 were 
seeded at 1x105 and cultured in RPMI 1640 10% Fetal 
Calf Serum (FCS) (Euroclone). After 4 days of culture, 
the cells were centrifuged at 1500 RPM for 10 min and 
the supernatants were filtered through a 0.2 µm filter. 
Monoclonal antibodies used for FACS analysis and 
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days. SB 203580 did not have any effect on the cell yield 
whereas PD98059 reduced the cell number.
Immunoblotting
After 6 days of culture, DC were lysed with 100 µL 
lysis buffer (Cell Signaling Technology). The lysates (100 
µg) were then resolved by SDS-PAGE and transferred to 
nitrocellulose membranes (Bio-Rad). The levels of the 
phosphorylated STAT3, p38MAPK, ERK were detected 
using phospho-specific antibodies. Antibodies directed 
against the total proteins and β-actin were also used 
and the reactions were visualized by using a goat anti-
mouse horseradish peroxidase conjugate antibody (Cell 
Signaling Technology) and enhanced chemiluminescence 
(Amersham).
Flow cytometric analysis
For immunophenotyping, cells were washed in PBS 
and incubated for 30 min at 4°C with the following 
monoclonal antibodies: CD14 and CD1a (Becton and 
Dickinson). For the unconjugated antibodies the binding 
was revealed by goat  FITC-conjugated anti-mouse Ig 
(Cappel). The samples were analyzed using a FACScan 
cytometer (Becton and Dickinson).
Mixed lymphocyte reaction
MLR were performed on immature DC obtained after 
6 days of culture or on mature DC obtained by adding LPS 
from Salmonella abortus equi (1µg/ml) for an additional 
48 hours. The assay was carried out in 96-well flat-bottom 
microtiter plates by adding different numbers of irradiated 
(3000 rad) DC to 2x105 allogeneic PBL. At day 6 of 
culture at 37°C, cell proliferation was assessed by uptake 
of 3H thymidine (1µCi/well) added for the last 16 hours.
Immunofluorescence
After 6 days of culture, DC were washed with PBS 
and fixed with absolute methanol for 5 min at -20°C. 
Cells were then incubated for 1 h with rabbit polyclonal 
antibody to NFkB p65 (Santa Cruz), rinsed 3 times with 
PBS and then incubated with FITC-conjugated anti-rabbit 
IgG (Sigma) for 1 h. Cells were then rinsed 3 times with 
PBS and mounted with Prolong anti-fast reagent and 
the fluorescence was analysed by an Olympus BX52 
fluorescence microscope. The images were acquired and 
elaborated with IAS 2000 software.
RESULTS
PEL-released factors hyperphosphorylate STAT3 
and p38 MAPK in monocyte derived DC
The cytokines IL-6, IL-10 and VEGF released 
by PEL cell lines and detected in PEL supernatants 
are known to converge in hyperphosphorylation of 
STAT3, in an autocrine fashion. To verify whether 
they also hyperphosphorylate STAT3 in monocyte-
derived DC in a paracrine fashion, we performed a 
western blot analysis using a specific antibody against 
p-STAT3. As shown in Fig. 1, the DC obtained in 
the presence of PEL (BC3) supernatant showed an 
increase of STAT3 tyrosine-phosphorylation at Tyr-
705 after 6 days of culture when compared to the 
DC differentiated in the absence of PEL supernatant. 
Similar results were obtained with three different 
donors and two additional PEL supernatants (JSC1 
and BCP1, data not shown). We then blocked STAT3 
hyperphosphorylation in monocyte-differentiating 
DC by using a JAK2/STAT3 inhibitor AG 490 at 10 
mM for 2 hours before starting the culture with GM-
CSF and IL-4 plus the PEL supernatant. On day 6 of 
culture we performed a western blot analysis also 
on DC obtained in the presence of AG490 and the 
results obtained indicate that this inhibitor was able 
to reduce STAT3 phosphorylation induced by PEL 
supernatant (Fig. 1). Similar results were obtained 
with JSI-124, which was added to the CD14 culture 
on day 4 of culture at 0.5 mM and kept for the last 
48 hours (data not shown). Other abnormal signaling 
pathways are reported to be associated with tumor 
inhibition of DC differentiation such as p38 MAPK 
pathway that seems to be the most important pathway 
in the DC dysfunction in multiple myeloma (12-13). 
We investigated the protein level of phosphorylated 
p38 MAPK and ERK in the DC obtained in the 
presence or in the absence of PEL supernatants. The 
results shown in Fig. 2 indicate that DC obtained in 
the presence of PEL supernatant, display an increase 
of p38 MAPK phosphorylation while no modification 
of ERK phopsphorylation was observed. The effect 
of p38 MAPK specific inhibitor SB203580 on 
p38 phosphorylation is also shown. The lack of 
quantitative difference in pp38 levels in SB203580-
treated DC is most probably due to the fact that this 
inhibitor does not block the phosphorylation but 
inhibits the kinase activity (13).
P38 MAPK but not Jak2/STAT3 specific inhibitor 
partially reverts the effect of PEL supernatant on 
DC differentiation
To determine the causal relationship between 
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the abnormal signaling and the impairment of DC 
differentiation observed in the presence of PEL 
released factors, we pretreated CD14+ monocytes 
with Jak2/STAT3 inhibitor AG490 or p38 MAPK 
inhibitor SB203580 before exposure to the PEL 
supernatant and to the differentiation cocktail. To 
answer the question whether the inhibition of DC 
differentiation observed in the presence of PEL 
supernatant could depend on STAT3 and/or p38 
MAPK hyperphosphorylation, we performed a FACS 
analysis on DC obtained in the presence of PEL 
supernatant with or without inhibitors. We analyzed 
the surface expression of molecules modified during 
the monocyte differentiation into DC in the presence 
of PEL-released factors and in  particular the 
expression of CD1a, which was strongly reduced and 
CD14, which was not lost in the DC differentiated in 
the presence of PEL supernatant (Fig. 3C). The results 
obtained with the use of kinase inhibitors indicate that, 
while the inhibition of p38 MAPK with SB203580 
partially reverted the effect of PEL supernatant on 
these differentiation markers (Fig. 3D), AG490 did 
not modify the expression of CD14 and CD1a (Fig. 
3E). The mean percentage positive cells plus standard 
deviation (SD) of four experiments is the following: 
control DC-81.6±15, spnt-treated DC-19.5±11, spnt-
DC plus SB203580-56±20 and spnt-DC plus AG-
49027.2±6. No significant modification on the CD83 
and 86 costimulatory molecules was observed in the 
presence or in the absence of PEL supernatant or with 
the kinase inhibitors (data not shown). To investigate 
whether inhibition of STAT3 or p38 MAPK 
phosphorylation could have also an effect in restoring 
DC function, we performed an MLR assay on the 
DC treated with PEL supernatant in the presence or 
in the absence of AG490 and SB204580. As shown 
in Fig. 4a, the DC obtained in the presence of both 
inhibitors, alone or in combination, did not recover 
the allostimulatory capacity reduced by PEL. Nor was 
the allostimulatory function of DC restored after their 
complete maturation with LPS (Fig. 4b). 
Effect of PEL-released fctors on NF-kappaB 
activation on monocyte derived DC
Since NF-kappaB activation is essential for the 
allostimulatory activity of the DC, we evaluated its 
status in DC. The active NF-kappaB translocates 
into the nucleus from the cytoplasm where it is 
present in an inactive form. In these experiments we 
performed immunofluorescence detection of the Rel 
A subunit of NF-kappaB since it has been reported 
that p50 and RelA may be the most important NF-
Fig. 1. STAT3 activation in PEL-mediated blocking of 
DC differentiation. Level of STAT3 phosphorylation (p-
STAT3) in the DC differentiated in the absence, in the 
presence of PEL supernatant or in the presence of PEL 
supernatant plus Jak2/STAT3 inhibitor AG490. Level of 
total STAT3 (t-STAT3) and β-actin is also shown. Data for 
one of three representative donors is shown.
Fig. 2. p38 MAPK activation in PEL-mediated blocking 
of DC differentiation. Level of p38 MAPK and ERK 
phosphorylation in the DC differentiated in the absence 
or in the presence of PEL supernatant or in the presence 
of PEL supernatant plus p38 MAPK inhibitor SB203580. 
Level of total p38 and ERK molecules and β-actin is also 
shown. Data for one of three representative donors is 
shown.
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kappaB subunits in developing DC (17). 
As shown in Fig. 5a, NF-kappaB is activated 
and translocates to the nuclei in 20% of control 
DC while in DC obtained in the presence of PEL-
released factors it was retained in the cytoplasm in 
approximately all of the cells (Fig. 5b). We further 
investigated whether the use of AG490 or SB203580 
could restore NF-kappaB traslocation and activation 
inhibited by PEL supernatant. In Fig. 5 c and d, we 
show that the use of AG490 or SB203580 was not 
sufficient to reactivate NF-kappaB and probably this 
can be one of the reasons why MLR function was not 
resored in these DC. 
DISCUSSION
It is well-documented that differentiation and 
function of DC in cancer patients are impaired 
due to the tumor cells or tumor-derived cytokines 
and other released factors (18-19). The defective 
differentiation of tumor patient-derived DC could 
be due also to defects in the progenitor cells from 
patients. Studies on PEL patient ex vivo-generated 
DC are lacking. We have recently shown that 
supernatants of PEL cell lines are able to inhibit the 
in vitro differentiation of DC from CD14+ monocytes. 
In our study, the abnormal DC differentiation 
is observed utilizing, as precursors, monocytes 
derived from healthy donors and the inhibition of 
DC differentiation is completely due to the PEL-
released factors and in particular to IL-6, IL-10 
and VEGF (14). Their role has been highlighted by 
the use of neutralizing antibodies. These cytokines 
converge in the hyperphosphorylation of STAT3 and 
the consequent aberrant activation of STAT3 plays a 
pivotal role in the negative regulation of antitumor 
immunity (10, 18). Other pathways, such as p38 
MAPK, can be activated by tumor-released factors 
and interfere with DC differentiation, as reported 
for multiple myeloma (12). In the present work, we 
show that PEL-released factors hyperphosphorylate 
STAT3 and p38 MAPK molecules in monocyte-
derived DC. To investigate which signaling pathway 
plays a major role in the defect of DC differentiation 
and function, specific inhibitors for kinases were 
used. SB203580 (p38 inhibitor), but not AG490 
(STAT3 inhibitor), was able to restore the monocyte 
differentiation into DC, as indicated by the CD1a 
expression. However, neither AG490 nor SB203580 
were able to restore the DC function and in particular 
the MLR capacity. These results suggest that 
additional pathways are involved in the upregulation 
of CD1a molecule and the function of DC and that at 
least the MLR capacity probably correlate more with 
CD86 and CD83 expression, which were indeed not 
modified by p38 and STAT3 inhibitors (data not 
Fig. 3. Effect of PEL released factors in the presence or in 
the absence of AG490 and SB203580 on DC differentiation 
markers. CD1a and CD14 immunofluorescence were 
detected by flow cytometry. A: isotype control, B: DC 
obtained with a cocktail of IL-4 and GM-CSF, C: DC 
obtained in the presence of 20% BC3 supernatant, D: As 
in C+SB203580, E: As in C+AG490. One representative 
experiment out of four is shown. The numbers represent 
the percentage of positive cells. 
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either of the two inhibitors and this suggests that 
tumors factors other than p38 MAPK and STAT3 are 
involved in the inhibition of NF-kappaB. STAT3 is 
crucial for tumor-cell proliferation and survival for 
many tumors, including PEL (5), and its constitutive 
activation can be propagated from tumor cells to the 
cells of the immune system with inhibitory effect 
on its function. Indeed, it has been reported that, 
besides acting as a chemotherapeutic drug, STAT3 
inhibitors can improve the DC activity against some 
types of tumors (7). However, a previous paper on 
DC defect in multiple myeloma showed that, in spite 
of the presence of hyperphosphorylated STAT3, 
the activation of p38 MAPK signaling pathways, 
together with inhibition of MEK/ERK, is the major 
contributor to the abnormalities of these monocyte-
derived DC (12). Our results that p38 MAPK pathway 
is more important than STAT3 for the inhibition of 
DC differentiation in PEL are consistent with similar 
observation in myeloma and are also in agreement 
with previous studies showing that p38 MAPK 
activation inhibits DC differentiation (16). On the 
contrary, during the maturation, its activation has a 
positive role (21-22). Moreover, we found that the 
PEL-released factors inhibited NF-kappaB molecule, 
which is normally activated and translocated to the 
nucleus in monocyte-derived DC (16). Removing 
the inhibitory effect of STAT3 and p38 by using 
AG490 and SB203580 was not sufficient to restore 
NF-kappaB activation. Progress in signaling 
pathways involved in DC maturation has been made 
shown).  In addition, the presence of the above 
inhibitors did not reactivate NF-kappaB, which 
resulted inhibited and remained in the cytoplasm 
in the DC differentiated in the presence of PEL-
released factors. It was previously reported, with 
different approaches, that allostimulatory function of 
DC is dependent on NF-kappaB activation (20). We 
were not able to see activation of NF-kappaB with 
Fig. 4. Mixed Lymphocyte Reaction (MLR) of immature (a) and mature DC (b) differentiated in the absence or in the 
presence of PEL released factors with or without AG490 or SB203580. Each bar represents the mean plus the standard 
deviation of 3H-thymidine incorporation of three different experiments. Ratio DC:T=1:10 
Fig. 5. NF-kappaB activity in DC differentiated in the 
absence (a) or in the presence (b) of PEL released factors 
with AG490 (c) and SB203580 (d). Immunofluorescence 
detection of Rel A subunit of NF-kappaB. One 
representative experiment out of two is shown.
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over the past several years, while the molecular 
events involved in the differentiation and generation 
of immature DC are still poorly characterized. This 
study provides important insight into the molecular 
mechanisms regulating the DC differentiation and 
in particular its inhibition in the presence of soluble 
factors released by PEL. Further studies are needed 
to clarify the molecular pathways underlying the 
molecular defects of DC found in cancer patients 
(23) since DC-based immunotherapy holds great 
promise for treating human malignancies.
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PERIODONTITIS: FROM LOCAL INFECTION TO SYSTEMIC DISEASES
F.  D’AIUTO1, F. GRAZIANI1,2, S. TETÈ 3, M. GABRIELE 2 and M.S. TONETTI 4
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Chieti, Italy;4Department of Periodontology, University of Connecticut, Farmingdon, CT, USA
The first two authors equally contributed to the review
Periodontitis is a chronic infectious disease, characterized by the progressive loss of the teeth’s 
supporting tissues, affecting almost 40% of the entire adult population. An imbalance between a 
localized gram-negative infection and an exaggerated host inflammatory response plays a pivotal role 
in determining gingival tissue damage. Recent evidence suggests that the effect of periodontitis might 
not be limited just to the oral cavity but it might have systemic consequences. Indeed periodontitis has 
also been associated with a moderate systemic inflammatory response. Although the mechanisms behind 
this association remain unclear, periodontitis might represent one distant source of low-grade systemic 
inflammation. This association could explain the increased risk of future cardiovascular diseases 
observed, the impaired metabolic control in diabetes subjects and the adverse pregnancy outcomes 
observed in populations suffering from periodontitis. In this review we describe the pathophysiological 
processes involved in periodontitis and briefly review the evidence produced to support an association 
between periodontitis and systemic diseases.
The concept that oral infections might influence 
systemic health is not new and has always been one 
of great interest. The term “oral sepsis”, later called 
“focal infection”, circulated among physicians at the 
beginning of the last century (1). At that time it was 
postulated that distant “foci” of tissue infections (e.g. 
complicated carious lesions, advanced periodontitis) 
might be harmful for other body areas and therefore 
a tremendous effort to remove them (indiscriminate 
tooth extractions) developed (1). With time and new 
clinical evidence, the focal infection theory collapsed, 
since such an approach proved unbeneficial in treating 
serious systemic diseases (rheumatism, arthritis, 
kidney diseases) (1). 
The focal hypothesis has seen new light in the past 
decade since a series of research investigations have 
associated periodontal disease with various systemic 
diseases (cardiovascular disease, diabetes, pulmonary 
infections and adverse pregnancy outcomes). The 
aim of this review is to focus on the pathobiology of 
periodontitis and its link with systemic inflammation, 
which might explain the increased risk of systemic 
diseases observed in this patient population. 
Periodontitis 
Periodontitis is a multi-factorial, chronic 
infectious disease characterized by the loss of 
the connective tissue attachment to the teeth and 
resorption of the alveolar bone (2). The process 
is initiated by the accumulation of a dental plaque 
biofilm on the tooth surface near the gingival margin 
(3-4). It is a common disease. Moderate 
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